Economic evaluation of a community-based diagnostic pathway to stratify adults for non-alcoholic fatty liver disease: a Markov model informed by a feasibility study

Objectives: To assess the long-term cost-effectiveness of a risk stratification pathway, compared with standard care, for detecting non-alcoholic fatty liver disease (NAFLD) in primary care. Setting: Primary care general practices in England. Participants: Adults who have been identified in pr...

Full description

Bibliographic Details
Main Authors: Tanajewski, Lukasz, Harris, Rebecca, Harman, David J., Aithal, Guruprasad P., Card, Timothy R., Gkountouras, Georgios, Berdunov, Vladislav, Guha, Indra Neil, Elliott, Rachel
Format: Article
Published: BMJ Publishing Group Ltd 2017
Subjects:
Online Access:https://eprints.nottingham.ac.uk/42585/
_version_ 1848796519773241344
author Tanajewski, Lukasz
Harris, Rebecca
Harman, David J.
Aithal, Guruprasad P.
Card, Timothy R.
Gkountouras, Georgios
Berdunov, Vladislav
Guha, Indra Neil
Elliott, Rachel
author_facet Tanajewski, Lukasz
Harris, Rebecca
Harman, David J.
Aithal, Guruprasad P.
Card, Timothy R.
Gkountouras, Georgios
Berdunov, Vladislav
Guha, Indra Neil
Elliott, Rachel
author_sort Tanajewski, Lukasz
building Nottingham Research Data Repository
collection Online Access
description Objectives: To assess the long-term cost-effectiveness of a risk stratification pathway, compared with standard care, for detecting non-alcoholic fatty liver disease (NAFLD) in primary care. Setting: Primary care general practices in England. Participants: Adults who have been identified in primary care to have a risk factor for developing NAFLD, that is, type 2 diabetes without a history of excessive alcohol use. Intervention: A community-based pathway, which utilises transient elastography and hepatologists to stratify patients at risk of NAFLD, has been implemented and demonstrated to be feasible (NCT02037867). Earlier identification could mean earlier treatments, referral to specialist, and enrolment into surveillance programmes. Design: The impact of earlier detection and treatment with the risk stratification pathway on progression to later stages of liver disease was examined using decision modelling with Markov chains to estimate lifetime health and economic effects of the two comparators. Data sources: Data from a prospective cross-sectional feasibility study indicating risk stratification pathway and standard care diagnostic accuracies, were combined with a Markov model that comprised the following states: no/mild liver disease, significant liver disease, compensated cirrhosis; decompensated cirrhosis, hepatocellular carcinoma, liver transplant and death. The model data were chosen from up-to-date UK sources, published literature and an expert panel. Outcome measure: An incremental cost-effectiveness ratio (ICER) indicating cost per quality adjusted life year (QALY) of the risk stratification pathway compared with standard care was estimated. Results: The risk stratification pathway was more effective than standard care, and cost £2,138 per QALY gained. The ICER was most sensitive to estimates of the rate of fibrosis progression and the effect of treatment on reducing this, and ranged from -£1,895 to £7,032/QALY. The risk stratification pathway demonstrated an 85% probability of cost-effectiveness at the UK willingness-to-pay threshold of £20,000/QALY. Conclusions: Implementation of a community-based risk stratification pathway is likely to be cost effective.
first_indexed 2025-11-14T19:49:17Z
format Article
id nottingham-42585
institution University of Nottingham Malaysia Campus
institution_category Local University
last_indexed 2025-11-14T19:49:17Z
publishDate 2017
publisher BMJ Publishing Group Ltd
recordtype eprints
repository_type Digital Repository
spelling nottingham-425852020-05-04T18:54:09Z https://eprints.nottingham.ac.uk/42585/ Economic evaluation of a community-based diagnostic pathway to stratify adults for non-alcoholic fatty liver disease: a Markov model informed by a feasibility study Tanajewski, Lukasz Harris, Rebecca Harman, David J. Aithal, Guruprasad P. Card, Timothy R. Gkountouras, Georgios Berdunov, Vladislav Guha, Indra Neil Elliott, Rachel Objectives: To assess the long-term cost-effectiveness of a risk stratification pathway, compared with standard care, for detecting non-alcoholic fatty liver disease (NAFLD) in primary care. Setting: Primary care general practices in England. Participants: Adults who have been identified in primary care to have a risk factor for developing NAFLD, that is, type 2 diabetes without a history of excessive alcohol use. Intervention: A community-based pathway, which utilises transient elastography and hepatologists to stratify patients at risk of NAFLD, has been implemented and demonstrated to be feasible (NCT02037867). Earlier identification could mean earlier treatments, referral to specialist, and enrolment into surveillance programmes. Design: The impact of earlier detection and treatment with the risk stratification pathway on progression to later stages of liver disease was examined using decision modelling with Markov chains to estimate lifetime health and economic effects of the two comparators. Data sources: Data from a prospective cross-sectional feasibility study indicating risk stratification pathway and standard care diagnostic accuracies, were combined with a Markov model that comprised the following states: no/mild liver disease, significant liver disease, compensated cirrhosis; decompensated cirrhosis, hepatocellular carcinoma, liver transplant and death. The model data were chosen from up-to-date UK sources, published literature and an expert panel. Outcome measure: An incremental cost-effectiveness ratio (ICER) indicating cost per quality adjusted life year (QALY) of the risk stratification pathway compared with standard care was estimated. Results: The risk stratification pathway was more effective than standard care, and cost £2,138 per QALY gained. The ICER was most sensitive to estimates of the rate of fibrosis progression and the effect of treatment on reducing this, and ranged from -£1,895 to £7,032/QALY. The risk stratification pathway demonstrated an 85% probability of cost-effectiveness at the UK willingness-to-pay threshold of £20,000/QALY. Conclusions: Implementation of a community-based risk stratification pathway is likely to be cost effective. BMJ Publishing Group Ltd 2017-07-05 Article PeerReviewed Tanajewski, Lukasz, Harris, Rebecca, Harman, David J., Aithal, Guruprasad P., Card, Timothy R., Gkountouras, Georgios, Berdunov, Vladislav, Guha, Indra Neil and Elliott, Rachel (2017) Economic evaluation of a community-based diagnostic pathway to stratify adults for non-alcoholic fatty liver disease: a Markov model informed by a feasibility study. BMJ Open, 7 (6). pp. 1-11. ISSN 2044-6055 Cost effectiveness analysis Screening Transient elastography Fibrosis Quality-adjusted life-years http://bmjopen.bmj.com/content/7/6/e015659 doi:10.1136/bmjopen-2016-015659 doi:10.1136/bmjopen-2016-015659
spellingShingle Cost effectiveness analysis
Screening
Transient elastography
Fibrosis
Quality-adjusted life-years
Tanajewski, Lukasz
Harris, Rebecca
Harman, David J.
Aithal, Guruprasad P.
Card, Timothy R.
Gkountouras, Georgios
Berdunov, Vladislav
Guha, Indra Neil
Elliott, Rachel
Economic evaluation of a community-based diagnostic pathway to stratify adults for non-alcoholic fatty liver disease: a Markov model informed by a feasibility study
title Economic evaluation of a community-based diagnostic pathway to stratify adults for non-alcoholic fatty liver disease: a Markov model informed by a feasibility study
title_full Economic evaluation of a community-based diagnostic pathway to stratify adults for non-alcoholic fatty liver disease: a Markov model informed by a feasibility study
title_fullStr Economic evaluation of a community-based diagnostic pathway to stratify adults for non-alcoholic fatty liver disease: a Markov model informed by a feasibility study
title_full_unstemmed Economic evaluation of a community-based diagnostic pathway to stratify adults for non-alcoholic fatty liver disease: a Markov model informed by a feasibility study
title_short Economic evaluation of a community-based diagnostic pathway to stratify adults for non-alcoholic fatty liver disease: a Markov model informed by a feasibility study
title_sort economic evaluation of a community-based diagnostic pathway to stratify adults for non-alcoholic fatty liver disease: a markov model informed by a feasibility study
topic Cost effectiveness analysis
Screening
Transient elastography
Fibrosis
Quality-adjusted life-years
url https://eprints.nottingham.ac.uk/42585/
https://eprints.nottingham.ac.uk/42585/
https://eprints.nottingham.ac.uk/42585/